Table 32. Patient characteristics–chlorpromazine versus quetiapine

| **Author, Year** | **Study Characteristics** | **Inclusion and Exclusion Criteria** | **Population** | **Interventions** |
| --- | --- | --- | --- | --- |
| **Peuskens et al. 1997**121 | ***Study design:*** RCT***Registration #:*** NR***Study population:*** Schizophrenia***DSM Classification:*** DSM–III–R***Study period:*** NR***Number of centers:*** Multicenter(n = 28)***Setting:*** Inpatient***Country:*** Belgium, UK, Spain, France, South Africa***Financial support:*** Industry (Zeneca)***Washout period performed:*** yes (24 h)***Run-in phase performed:*** no***Followup period:*** 6 wks | ***Main inclusion criteria:*** Age 18–65; acute exacerbation of chronic or subchronic Sz, or schizophreniform disorder; BPRS score = 27; BPRS pos score = 3 on two or more of 'conceptual disorganization', 'suspiciousness', 'hallucinatory behavior' and 'unusual thought content'; a score of = 4 on CGI–S.***Main exclusion criteria:*** Any medical condition or laboratory abnormality that might confound the trial results; had received long–acting depot medication; had participated in another investigational drug trial during the 4 wks prior to randomization; evidence of significant alcohol or other drug abuse within the previous 12 mo. | ***G1:******Age (mean±SD):*** 34.00±11.00***Males (n(%)):*** *66*/100 (66%)***Ethnicity:*** Caucasian 80/100(80%)***BL symptom scores:*** BPRS (mean±SD): 44±11PANSS (mean±SD): 27.8±8***G2:******Age (mean±SD):*** 32.00±10.00***Males (n(%)):*** 63/101 (62.4%)***Ethnicity:*** Caucasian 81/101 (80.2%)***BL symptom scores:*** BPRS (mean±SD): 46±10PANSS (mean±SD): 28±8 | ***G1:******Classification:*** FGA***Drug:*** Chlorpromazine***Dosage:*** 75–750mg/d***Intervals:*** TID***G2:******Classification:*** SGA***Drug:*** Quetiapine***Dosage:*** 75–750mg/d***Intervals:*** TID |

AP = antipsychotic; BL = baseline; BPRS = Brief Psychiatric Rating Scale; CGI = Clinical Global Impressions; d = day; DSM = Diagnostic and Statistical Manual of Mental Disorders; FGA = first-generation antipsychotic; mg = milligram; mo = month; n = number; NA = not applicable; NR = not reported; PANSS  = Positive and Negative Syndrome Scale; pts = patients; RCT = randomized controlled trial; SD = standard deviation; SGA = second-generation antipsychotic; Sz = schizophrenia; TID = Three times daily; Tx = treatment; wk = week; yr = year